Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells

被引:31
作者
Guo, Changjiang [1 ]
Wang, Xiaoyin [1 ]
Zhang, Huiyong [1 ]
Zhi, Lingtong [1 ]
Lv, Tanyu [1 ]
Li, Mingfeng [1 ]
Lu, Chengui [1 ]
Zhu, Wuling [1 ]
机构
[1] Xinxiang Med Univ, Synthet Biol Engn Lab Henan Prov, Sch Life Sci & Technol, Xinxiang, Henan, Peoples R China
关键词
Chimeric receptor; Structure modeling; Rational design; PD-1; NKG2D; Cytotoxicity; NKG2D RECEPTOR; MEMBRANE;
D O I
10.1016/j.molimm.2019.07.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells have the potential to provide the potential for the implementation of allogeneic "off-the-shelf" cellular therapy against cancers. Currently, most CARs are not optimized for NK cells, so new NK-tailored CARs are needed. Here, a major activating receptor of NK cells, NKG2D was harnessed to design different chimeric receptors that mediate strong NK cell signaling. In these NKG2D signaling-based chimeric receptors, the extracellular domain of inhibitory receptor PD-1 was employed to reverse the immune escape mediated by PD-1 ligands in the solid tumors. To achieve the rational design of chimeric PD1-NKG2D receptors, we developed a transmembrane protein tertiary structure prediction program (PredMP & I-TASSER) and optimized the conformation of the PD-1 ectodomain by genetically altering the sequences encoding the hinge and intracellular domain. Finally, we identified a chimeric PD1-NKG2D receptor containing NKG2D hinge region and 4-1 BB co-stimulatory domain to exhibit stable surface expression and mediate in vitro cytotoxicity of NK92 cells against various tumor cells. This strategy now provides a promising approach for the computer-aided design (CAD) of potent NK cell-tailored chimeric receptors with NKG2D signaling.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 34 条
[1]   A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells [J].
Chang, Yu-Hsiang ;
Connolly, John ;
Shimasaki, Noriko ;
Mimura, Kousaku ;
Kono, Koji ;
Campana, Dario .
CANCER RESEARCH, 2013, 73 (06) :1777-1786
[2]  
Chang ZNL, 2018, NAT CHEM BIOL, V14, P317, DOI [10.1038/NCHEMBIO.2565, 10.1038/nchembio.2565]
[3]   Fusion protein linkers: Property, design and functionality [J].
Chen, Xiaoying ;
Zaro, Jennica L. ;
Shen, Wei-Chiang .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (10) :1357-1369
[4]   The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure [J].
Garrity, D ;
Call, ME ;
Feng, JW ;
Wucherpfennig, KW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (21) :7641-7646
[5]   Targeting natural killer cells in cancer immunotherapy [J].
Guillerey, Camille ;
Huntington, Nicholas D. ;
Smyth, Mark J. .
NATURE IMMUNOLOGY, 2016, 17 (09) :1025-1036
[6]   Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells [J].
Han, Yali ;
Xie, Wei ;
Song, De-Gang ;
Powell, Daniel J., Jr. .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[7]   CAR T cell immunotherapy for human cancer [J].
June, Carl H. ;
O'Connor, Roddy S. ;
Kawalekar, Omkar U. ;
Ghassemi, Saba ;
Milone, Michael C. .
SCIENCE, 2018, 359 (6382) :1361-1365
[8]   Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies [J].
Jung, In-Young ;
Lee, Jungmin .
MOLECULES AND CELLS, 2018, 41 (08) :717-723
[9]   4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells [J].
Kim, Young-June ;
Han, Myung-Kwan ;
Broxmeyer, Hal E. .
BLOOD, 2008, 111 (03) :1378-1386
[10]   NKG2D Receptor and Its Ligands in Host Defense [J].
Lanier, Lewis L. .
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (06) :575-582